A team of researchers has shown a link between low levels of adropin, a hormone that regulates glucose and fatty acid metabolism, and increased risk of metabolic diseases such as type 2 diabetes. The study found that low adropin levels were associated with obesity, insulin resistance, and other metabolic syndrome risk factors.
Researchers at Scripps Research Institute describe three human antibodies protecting against a wide variety of flu viruses, including Influenza B strains. These broadly neutralizing antibodies may provide key clues to designing an active universal flu vaccine.
Scientists have identified a new stem cell population that gives rise to neurons in the upper layers of the cerebral cortex, which are responsible for higher thinking. This finding paves the way for developing better treatments for cognitive disorders such as schizophrenia and autism by producing these neurons in culture.
Researchers found reducing copper in mice with prion disease delays onset by 20 days, with less abnormal protein in brains. However, study does not advocate for copper depletion as therapy and aims to learn more about copper function and prion disease biochemical workings.
A combination of naltrexone and buprenorphine has shown promise in reducing cocaine craving and blunting withdrawal symptoms in laboratory rats. This potential therapy, if proven safe and effective, would be a significant advance in treating cocaine addiction, which currently lacks FDA-approved medications.
Researchers at Scripps Florida are developing novel biochemical tests to identify inhibitors of the autophagy pathway, which can help overcome drug resistance and improve treatment efficacy for various cancers. The goal is to enhance the action of conventional anti-cancer therapeutics by targeting the critical on-off switch ULk1.
Researchers found tristetraprolin (TTP/ZFP36) to be a tumor suppressor that impairs lymphoma development and maintenance. The study's findings suggest TTP could be a key target for treating cancers with MYC involvement, including relapsed and refractory tumors.
Scientists at Scripps Research Institute mapped two essential cellular processes, revealing their cooperation during apoptosis. The study provides insights into programmed cell death and opens a new approach to cancer treatment.
Researchers at Scripps Research have identified a natural compound, Cortistatin A, that effectively reduces HIV replication by 99.7 percent in infected cells. The compound works by inhibiting the viral protein Tat, making it a promising potential treatment for the ongoing pandemic.
Recent studies have made significant progress in understanding GPCRs, shedding light on their structure and function. The high-resolution structures of several GPCR receptors, including the A2A adenosine receptor, have been determined, providing valuable insights into how these proteins interact with ligands.
The Scripps Research Institute has been awarded a grant to develop a vaccine against HIV and the disease it causes, AIDS. The Center for HIV/AIDS Vaccine Immunology & Immunogen Discovery (CHAVI-ID) will conduct multidisciplinary research into immune responses that prevent infection or control the virus in infected individuals.
Researchers have identified a crucial quality control mechanism in cell growth, ensuring proteins are produced correctly. The study sheds light on the assembly of ribosomes, complex machines inside cells responsible for producing proteins.
Scientists at Scripps Research Institute discovered a simple and safe method to disrupt specific genes within cells, offering a potential HIV treatment. The new technique uses zinc finger nuclease proteins, which can be added directly to cells without viral delivery methods.
Researchers at Scripps Research Institute have developed a powerful new technique for manipulating building-block molecules, enabling the creation of new drugs and organic chemicals. The method allows for controlled selectivity and reaction efficiency, overcoming technical obstacles that previously limited its use.
A study by Scripps Research Institute scientists shows that the single protein TLR7 plays a significant role in generating immune responses required to clear persistent LCMV infection. Without this protein, the immune system's ability to purge the infection is compromised, leading to exhaustion of T cells and impairment of both cellula...
Scientists at Scripps Research Institute developed a new chemical-screening method to find anti-HIV compounds targeting the nucleocapsid protein. The method yielded two effective and safe inhibitors with demonstrated anti-HIV activity in cell culture tests, offering hope for the development of new HIV treatments.
Researchers have identified a pair of proteins, RGS7 and RGS11, that play an essential role in vision, particularly in dim light environments. The study reveals that these proteins help regulate cells' response to light, enabling the transmission of visual information to the brain.
Researchers have developed chemical compounds that selectively block the attachment of sugar molecules to cells, potentially leading to new treatments for chronic inflammation, autoimmune diseases, and cancer. The new tools can help scientists understand how glycans influence cell function and behavior.
Scientists at Scripps Research Institute discover that unnatural DNA bases can replicate efficiently, suggesting an expanded genetic alphabet could carry more information. The finding has implications for the origins of life and the development of novel molecular tools.
Richard Lerner's discovery of combinatorial antibody libraries has led to the development of two market-leading drugs, Humira and Benlysta, alleviating suffering from autoimmune diseases. His work has significantly impacted disease treatment and prevention, showcasing his dedication to advancing human health.
The Esther B. O'Keeffe Charitable Foundation has donated $2 million to the Scripps Research Institute to support biomedical research and education. The gift will fund special initiatives on the Florida campus, including state-of-the-art scientific infrastructure and graduate student programs.
The study reveals that tafamidis works by stabilizing the transthyretin (TTR) protein tetramer, preventing it from aggregating into amyloids. This stabilization prevents nerve destruction in polyneuropathy patients and delays disease progression.
Researchers aim to break nicotine addiction by blocking hypocretin-1 receptors, which play a key role in driving desire for more nicotine. The study has the potential to provide a significant breakthrough in treating tobacco abuse and preventing relapse.
Scientists at Scripps Research Institute have discovered the first chemical compounds that inhibit PRMT1, an enzyme linked to asthma, arthritis, and certain cancers. The new inhibitors were identified using a selective screening technique that targets a specific amino acid found on PRMT1.
Researchers have identified two dopamine receptors, dDA1 and DAMB, that play a crucial role in regulating memory formation and forgetting. The study found that the dDA1 receptor is essential for memory acquisition, while the DAMB receptor triggers forgetting of recently acquired but not yet consolidated memories.
Researchers found that T-bet and RORα proteins enforce specific classes of memory B cells, which can produce antibodies against various infections. This discovery opens the way for developing vaccines that induce long-term immunity towards desired antibody classes.
A gene duplication, occurring 2.4 million years ago, allowed maturing neurons to migrate farther and develop more connections. This extra copy of the SRGAP2 gene interfered with its original function, effectively giving neurons more time to wire themselves into a bigger brain.
Researchers discovered dynamic changes in gene regulation in human stem cells, affecting their ability to serve as models for human disease and development. The study found that these cells can change their epigenomes, leading to unexpected outcomes in cell-based models of diseases like Lesch-Nyhan disease.
A Scripps Research Institute scientist has developed a novel method to design small molecule therapeutics targeting RNA, leveraging a bottom-up approach that uses information on RNA folds and internal loops. The successful designs have shown strong activity against myotonic dystrophy type 1, a common form of muscular dystrophy.
Researchers have determined the three-dimensional atomic structure of Argonaute2, a key 'gene silencer' protein involved in regulating cell activities. This discovery paves the way for understanding RNA-silencing and harnessing it to treat diseases by designing better therapeutic guide RNAs.
Researchers have detailed the signaling pathway from nitric oxide to biofilm formation in bacteria, which may aid in developing new treatments targeting biofilms. The study reveals a complex system of response regulators controlling biofilm formation.
Researchers found gabapentin significantly reduces cannabis use and withdrawal symptoms, improving cognitive skills. The study suggests gabapentin could become first FDA-approved treatment for cannabis dependence.
A Scripps Research Institute scientist has been awarded a $1 million grant to develop new tests for stress-associated diseases, including atherosclerosis, Alzheimer's disease, and Parkinson's disease. The goal is to identify drug leads that can prevent oxidative damage in zebrafish.
A team led by Martin Friedlander at Scripps Research Institute has received a $10.2 million grant to develop a new treatment strategy for diabetic retinopathy, macular degeneration, and other vision disorders. The approach targets a strand of micro-RNA that promotes abnormal blood vessel growth.
James Hoch's research aims to understand bacterial signaling interactions and their role in disease. His work has identified strategies for disrupting virulence factors and essential bacterial functions, suggesting potential approaches to treating antibiotic-resistant infections.
Researchers at Scripps Research Institute have developed an injectable solution that protects mice from cocaine overdose, demonstrating the therapeutic potential of a human antibody against cocaine. The treatment shows promise in reducing mortality rates and signs of overdose in both preliminary tests.
Researchers aim to identify compounds disabling the NS2 protein, crucial for HCV replication, with a novel high-throughput screening test. The goal is to develop chemical tools to study NS2's role in HCV biology and potentially discover new treatments.
Researchers found antibodies that can prevent infection from widely differing strains of HCV in cell culture and animal models. The newly discovered antibodies attach to sites on the viral envelope that seldom mutate, making them promising targets for an HCV vaccine.
Researchers found that stimulating specific neurons can reverse age-related memory defects in fruit flies, which may have implications for human memory disorders. The study used functional cellular imaging to monitor neuron activity and showed that cold-activated ion channels can rescue intermediate-term memory.
Scientists will investigate the role of Myc oncoproteins and a specific mRNA-binding protein, TTP, in controlling tumor growth. The study aims to define mechanisms that could lead to the development of new anti-cancer drugs.
Scientists at Scripps Research Institute created compounds that dramatically alter the biological clock, resulting in weight loss and improved metabolic markers in diet-induced obese mice. The study suggests potential effectiveness in treating obesity, diabetes, high cholesterol, and sleep disorders.
The Scripps Research Institute has received a $206,250 grant from the California Institute for Regenerative Medicine (CIRM) to expand its high school summer internship program. The program aims to inspire talented students from diverse backgrounds to pursue careers in stem cell research.
Researchers have successfully harnessed neurons in mouse brains, allowing them to at least partially control a specific memory. The study advances understanding of how memories form and offers new insight into disorders such as schizophrenia and post-traumatic stress disorder.
Researchers at Scripps Research Institute have determined the three-dimensional atomic structure of a human opioid receptor, a molecule that binds to opioids and is involved in pain, pleasure, addiction, depression, and related conditions. The findings could lead to the development of better medicine for these conditions.
Scientists from Scripps Research Institute have discovered a compound, SR 3306, that blocks the destruction of brain cells in animal models of Parkinson's disease. The new compound could potentially be the first to protect the brain from the ravages of the disease.
Researchers will focus on inhibiting cancer cell metabolism by targeting Mct1 and Mct4 proteins, which transport lactic acid out of cancer cells. The goal is to develop broad-spectrum anti-cancer therapeutics for breast cancer and lymphoma.
Researchers aim to create potent pain relievers with reduced side effects by studying four new compounds that avoid recruiting the protein beta arrestin 2. Genetic studies have shown animal models lacking beta-arrestins experience robust pain relief with diminished side effects.
A Scripps Florida team has been awarded nearly $1.5 million to identify and develop novel potent inhibitors of the human immunodeficiency virus (HIV). The research targets the capsid protein, a critical component of HIV, with the goal of creating new treatments for HIV-infected patients.
Scientists at Scripps Research Institute have uncovered a self-sustaining signaling circuit in breast cells that leads to cancer. This circuit is triggered by the activation of MEK/ERK and IKK/NF-kB pathways, which maintain the malignant state of tumor cells.
Researchers designed a series of small molecules that target an RNA defect causing myotonic dystrophy type 1. These compounds improve biological defects in cell culture and animal models by more than 40 percent.